Better late than never for Datroway in lung cancer
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
But the former is paying a fraction of what Merck shelled out for raludotatug.
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
Crunch time approaches for UroGen.